Document is current
Any future updates will be listed below
-
Authors
Mason, Jeremy W.
Chow, Yuen Ting https://orcid.org/0000-0002-9483-7324
Hudson, Liam https://orcid.org/0009-0000-8844-0059
Tutter, Antonin
Michaud, Gregory https://orcid.org/0000-0003-3954-4921
Westphal, Matthias V. https://orcid.org/0000-0003-0693-0789
Shu, Wei https://orcid.org/0000-0003-3259-6059
Ma, Xiaolei
Tan, Zher Yin https://orcid.org/0000-0003-2498-043X
Coley, Connor W. https://orcid.org/0000-0002-8271-8723
Clemons, Paul A. https://orcid.org/0000-0002-1800-5112
Bonazzi, Simone
Berst, Frédéric
Briner, Karin
Liu, Shuang https://orcid.org/0000-0003-3287-2404
Zécri, Frédéric J. https://orcid.org/0000-0002-2469-8875
Schreiber, Stuart L. https://orcid.org/0000-0003-1922-7558
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM127045)
- License Information
-
More Information
Article History
Received: 26 October 2022
Accepted: 24 September 2023
First Online: 2 November 2023
Competing interests
: X.M. is a shareholder of Terremoto Biosciences. C.W.C. is an advisor to Anagenex. P.A.C. is an advisor to nference, Pfizer and Belharra Therapeutics. S.L.S. is a shareholder and serves on the Board of Directors of Jnana Therapeutics and Kojin Therapeutics; is a shareholder and advises Kisbee Therapeutics, Belharra Therapeutics, Magnet Biomedicine, Exo Therapeutics and Eikonizo Therapeutics; advises Vividian Therapeutics, Eisai Co, Ono Pharma Foundation, F-Prime Capital Partners and the Genomics Institute of the Novartis Research Foundation and is a Novartis Faculty Scholar. The remaining authors declare no competing interests.
